Clinical effectiveness of platelets in additive solution treated with two commercial pathogen-reduction technologies

Transfusion

Volumn 57, Issue 5, 2017, Pages 1171-1183

  Rebulla, Paolo ^a   Vaglio, Stefania ^b   Beccaria, Francesco ^c   Bonfichi, Maurizio ^d   Carella, Angelo ^c   Chiurazzi, Federico ^e   Coluzzi, Serelina ^f   Cortelezzi, Agostino ^a   Gandini, Giorgio ^g   Girelli, Gabriella ^f   Graf, Maria ^e   Isernia, Paola ^d   Marano, Giuseppe ^b   Marconi, Maurizio ^a   Montemezzi, Rachele ^g   Olivero, Barbara ^a   Rinaldi, Marianna ^g   Salvaneschi, Laura ^d   Scarpato, Nicola ^e   Strada, Paolo ^c   Milani, Silvano ^h   Grazzini, Giuliano ^b   more..

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^e FEDERICO II UNIVERSITY HOSPITAL   (Italy)

^f POLICLINICO UMBERTO I   (Italy)

^g UNIVERSITY HOSPITAL OF VERONA   (Italy)

^h UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG ADDITIVE;

APHERESIS; ARTICLE; BLEEDING; BLOOD COMPONENT; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; ERYTHROCYTE; ERYTHROCYTE TRANSFUSION; FEMALE; HEMATOPOIETIC STEM CELL; HUMAN; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; PATHOGEN REDUCTION SYSTEM; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; REMISSION; STEM CELL TRANSPLANTATION; THROMBOCYTE; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; ADOLESCENT; ADULT; ADVERSE EFFECTS; AGED; ANTISEPSIS; BLOOD STORAGE; CLINICAL TRIAL; DISEASE TRANSMISSION; HEMORRHAGE; MICROBIOLOGY; MIDDLE AGED; MULTICENTER STUDY; PREVENTION AND CONTROL; PROCEDURES; STANDARDS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTISEPSIS; BLOOD PRESERVATION; DISEASE TRANSMISSION, INFECTIOUS; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PLATELET COUNT; PLATELET TRANSFUSION; YOUNG ADULT;

EID: 85013764620     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.14042     Document Type: Article

References (37)

1. Prowse CV. Component pathogen inactivation: a critical review. Vox Sang 2013;104:183-99.
2. Salunkhe V, van der Meer PF, de Korte D, Seghatchian J, Gutiérrez L. Development of blood transfusion product pathogen reduction treatments: a review of methods, current applications and demands. Transfus Apher Sci 2015;52:19-34.
3. van Rhenen D, Gulliksson H, Cazenave JP, et al. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003;101:2426-33.
4. McCullough J, Vesole DH, Benjamin RJ, et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT trial. Blood 2004;104:1534-41.
5. Snyder E, McCullough J, Slichter SJ, et al. Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial. Transfusion 2005;45:1864-75.
6. Janetzko K, Cazenave JP, Klüter H, et al. Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set. Transfusion 2005;45:1443-52.
7. Kerkhoffs JL, van Putten WL, Novotny VM, et al. Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction. Br J Haematol 2010;150:209-17.
8. Mirasol Clinical Evaluation Study Group. A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology. Transfusion 2010;50:2362-75.
9. Lozano M, Knutson F, Tardivel R, et al. A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion. Br J Haematol 2011;153:393-401.
10. Knutson F, Osselaer J, Pierelli L, et al. A prospective, active haemovigilance study with combined cohort analysis of 19,175 transfusions of platelet components prepared with amotosalen-UVA photochemical treatment. Vox Sang 2015;109:343-52.
11. Łętowska M, Przybylska Z, Piotrowski D, et al. Hemovigilance survey of pathogen-reduced blood components in the Warsaw Region in the 2009 to 2013 period. Transfusion 2016;56 Suppl 1:S39-44.
12. Snyder EL, Stramer SL, Benjamin RJ. The safety of the blood supply-time to raise the bar. N Engl J Med 2015;372:1882-5.
13. Hong H, Xiao W, Lazarus HM, Good CD, Maitta RW, Jacobs MR. Detection of septic transfusion reactions to platelet transfusions by active and passive surveillance. Blood 2016;127:496-502.
14. Musso D, Cao-Lormeau VM, Gubler DJ. Zika virus: following the path of dengue and chikungunya? Lancet 2015;386:243-4.
15. Mowatt G, Bower DJ, Brebner JA, Cairns JA, Grant AM, McKee L. When is the 'right' time to initiate an assessment of a health technology? Int J Technol Assess Health Care 1998;14:372-86.
16. Custer B, Janssen MP. Alliance of Blood Operators Risk-Based Decision-Making (RBDM) Initiative. Health economics and outcomes methods in risk-based decision-making for blood safety. Transfusion 2015;55:2039-47.
17. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
18. Slichter SJ, Kaufman RM, Assmann SF, et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med 2010;362:600-13.
19. Dubois D, Dubois EF. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 1916;17:863-71.
20. Santner TJ, Snell MK. Small-sample confidence intervals for p1-p2 and p1/p2 in contingency tables. J Am Stat Assoc 1980;75:386-94.
21. Goldstein H. Multilevel statistical models. 4th ed. Chichester: Wiley; 2011.
22. Cook RJ, Heddle NM. Clinical trials evaluating pathogen-reduced platelet products: methodologic issues and recommendations. Transfusion 2013;53:1843-55.
23. Vamvakas EC. Meta-analysis of the randomized controlled trials of the hemostatic efficacy and capacity of pathogen-reduced platelets. Transfusion 2011;51:1058-71.
24. Vamvakas EC. Meta-analysis of the studies of bleeding complications of platelets pathogen-reduced with the Intercept system. Vox Sang 2012;102:302-16.
25. Cid J, Escolar G, Lozano M. Therapeutic efficacy of platelet components treated with amotosalen and ultraviolet A pathogen inactivation method: results of a meta-analysis of randomized controlled trials. Vox Sang 2012;103:322-30.
26. Butler C, Doree C, Estcourt LJ, et al. Pathogen-reduced platelets for the prevention of bleeding. Cochrane Database Syst Rev 2013;3:CD009072.
27. Osselaer JC, Doyen C, Defoin L, et al. Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use. Transfusion 2009;49:1412-22.
28. Kleinman S, Cameron C, Custer B, et al. Modeling the risk of an emerging pathogen entering the Canadian blood supply. Transfusion 2010;50:2592-606.
29. Custer B, Agapova M, Martinez RH. The cost-effectiveness of pathogen reduction technology as assessed using a multiple risk reduction model. Transfusion 2010;50:2461-73.
30. Berger K, Bauer M, Schopohl D, Henschler R, Ostermann H. Model calculations to quantify clinical and economic effects of pathogen inactivation in platelet concentrates. Onkologie 2013;36:53-9.
31. Lozano M, Cid J. Analysis of reasons for not implementing pathogen inactivation for platelet concentrates. Transfus Clin Biol 2013;20:158-64.
32. Girona-Llobera E, Jimenez-Marco T, Galmes-Trueba A, et al. Reducing the financial impact of pathogen inactivation technology for platelet components: our experience. Transfusion 2014;54:158-68.
33. McCullough J, Goldfinger D, Gorlin J, et al. Cost implications of implementation of pathogen-inactivated platelets. Transfusion 2015;55:2312-20.
34. Agapova M, Lachert E, Brojer E, Letowska M, Grabaarczyk P, Custer B. Introducing pathogen reduction technology in Poland: a cost-utility analysis. Transfus Med Hemother 2015;42:158-65.
35. Heddle NM, Lane SJ, Sholapur N, et al. Implementation and public acceptability: lessons from food irradiation and how they might apply to pathogen reduction in blood products. Vox Sang 2014;107:50-9.
36. Mufti NA, Erickson AC, North AK, et al. Treatment of whole blood (WB) and red blood cells (RBC) with S-303 inactivates pathogens and retains in vitro quality of stored RBC. Biologicals 2010;38:14-9.
37. Allain JP, Owusu-Ofori AK, Assennato SM, Marschner S, Goodrich RP, Owusu-Ofori S. Effect of plasmodium inactivation in whole blood on the incidence of blood transfusion-transmitted malaria in endemic regions: the African Investigation of the Mirasol System (AIMS) randomised controlled trial. Lancet 2016;387:1753-61.